Research Summary for 2019 for the Charity Report 2020

Mireia Jofre-Bonet
Office of Health Economics, London
# Table of Contents

1. **Foreword** .................................................................................................................. 1

2. **Review of OHE’s research programme in 2019** .......................................................... 1
   4.1 Core-funded Projects ............................................................................................... 1
   4.2 Research Output: ........................................................................................................ 5
       4.2.1 Publications: ....................................................................................................... 5
   **External Journals** ........................................................................................................ 6
   **OHE peer-reviewed** .................................................................................................... 7
   **Working papers in external sites** .................................................................................. 9
       4.2.2 Research Grants and Research Projects .............................................................. 9
   4.3 Lunch-time Seminars ................................................................................................. 10
   4.4 Brown-Bag Programme ............................................................................................. 11
   4.5 OHE Annual Lecture 2019 ..................................................................................... 11
   4.6 Other contributions by OHE to Research Output ....................................................... 12
       4.6.1 External presentations by OHE staff .................................................................. 12
       4.6.2 Advisory roles held by OHE staff members ......................................................... 27
       4.6.3 Examples of OHE’s impact ................................................................................ 29

5. **Research Plans for 2020** ........................................................................................... 30
   5.1 General Research Strategy ....................................................................................... 30
   5.2 Research Plans by Theme and Presentation by Leads ............................................... 31
       Judging Value for Money and Improving Decision-Making (Martina Garau) .......... 32
       Economics of Innovation (Mikel Berdud) .................................................................. 33
       Incentivising Quality (Margherita Neri) ..................................................................... 34
       Measuring and valuing outcomes (Patricia Cubi-Mollá) .............................................. 35

6. **Update on status of Independent Research Organisation Application** ................... 37

7. **Concluding Remarks** ................................................................................................. 38
1. Foreword

This report contains the summary of OHE research output in 2019, accompanying the Charity Report for 2019.

2. Review of OHE’s research programme in 2019

Below, we present a summary of all research output produced by OHE in 2019 organised in core funded projects by theme, publications, and research grants.

4.1 Core-funded Projects

<table>
<thead>
<tr>
<th>Economics of innovation</th>
<th>Investigators</th>
<th>Update on progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Establishing a reasonable price for an orphan drug</td>
<td>Mikel Berdud, Adrian Towse; Mike Drummond (York)</td>
<td>OHE Research Paper published in Jul 2018; manuscript submitted to Applied Health Economics and Health Policy in 2019.</td>
</tr>
<tr>
<td>Open innovation – at which state of R&amp;D collaboration might be more socially beneficial than competition</td>
<td>Adrian Towse; Jorge Mestre-Ferrandiz (OHE Visiting Fellow), Thomas Grieve (Oxford)</td>
<td>An early draft of the paper is ready; however, Thomas Grieve has left Oxford and the project. <a href="https://abpi.app.box.com/folder/87607364487">https://abpi.app.box.com/folder/87607364487</a></td>
</tr>
<tr>
<td>Adaptive Pathways</td>
<td>Adrian Towse, Mikel Berdud, Jorge-Mestre-Ferrandiz (OHE Visiting Fellow), Liz Fenwick (Pharmerit), Adam Heathfield (Pfizer)</td>
<td>1. OHE Research Paper (Berdud et al.: Modelling the value of early access schemes and adaptive pathway approaches) – ready for publication subject to final internal review by Adrian Towse. 2. OHE Research Paper (Towse and Fenwick: Use of VoI to analysis managed entry agreements and adaptive pathways) – in progress</td>
</tr>
<tr>
<td>Foresight study on European stakeholder appraisal of diagnostics to manage antimicrobial resistance</td>
<td>Grace Hampson, Adrian Towse, David Mott; Michael Hopkins, Martin Llewelyn, Andy Stirling, Frederique Lang (Sussex); Jorge Mestre-Ferrandiz (OHE Visiting Fellow)</td>
<td>A paper containing the lay survey results has been published in Applied Health Economics and Health Policy, with an accompanying blog. The authors plan to put together a policy brief upon publication of the 2nd paper.</td>
</tr>
<tr>
<td>Economics of innovative payment models compared with single pricing of pharmaceuticals</td>
<td>Amanda Cole, Adrian Towse, Bernarda Zamora; Paula Lorgelly (ex-OHE), Richard Sullivan (KCL)</td>
<td>Manuscript prepared and with the authors for internal review. First preference is for submission to the Journal of Cancer Policy – submitted in Q2 2019.</td>
</tr>
<tr>
<td>Debate on indication-based pricing and how it has been implemented in practice</td>
<td>Amanda Cole, Adrian Towse, Bernarda Zamora</td>
<td>Dropped, and material combined with paper above on economics of innovative payment mechanisms.</td>
</tr>
<tr>
<td>Project</td>
<td>Investigators</td>
<td>Update on progress</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Barriers to Uptake of Minimal Access Surgery in the United Kingdom</td>
<td>Phill O’Neill, Chris Sampson, Amanda Cole</td>
<td>One manuscript that was prepared for submission to BJU International is currently awaiting action from the original client. <a href="https://abpi.app.box.com/folder/70417601279">https://abpi.app.box.com/folder/70417601279</a></td>
</tr>
<tr>
<td>Value of Innovative Medicines: The Case of Risperidone and Second-generation Antipsychotics?</td>
<td>Mikel Berdud, N. Wallin-Bernhardsson (IHE), B. Zamora, P. Lindgren (IHE), and A. Towse</td>
<td>On-going.</td>
</tr>
<tr>
<td>A Dynamic Approach to Pharmaceutical Regulation: VBP and welfare maximisation</td>
<td>Mireia Jofre-Bonet, Niccolo Stamboglis (City), Alistair McGuire (LSE), and Sabine Grimm (Maastricht University Medical Centre)</td>
<td>This paper has been rewritten in collaboration with PhD student Niccolo. We are preparing to submit it to a peer review journal by December 2019. A blog post will be made when we have the final version. <a href="https://abpi.app.box.com/folder/89673561458">https://abpi.app.box.com/folder/89673561458</a></td>
</tr>
<tr>
<td>Patients’ choice and hospital quality competition: Unintended impacts of the signals</td>
<td>Tommaso Gabrieli (UCL), Mireia Jofre-Bonet, Alistair J. McGuire (LSE), and Matthew Skellem (NHS Improvement)</td>
<td>Work in progress.</td>
</tr>
</tbody>
</table>

**Judging value for money and improving decision-making**

<table>
<thead>
<tr>
<th>Project</th>
<th>Investigators</th>
<th>Update on progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valuing health at the end of life</td>
<td>Koonal Shah; Aki Tsuchiya (Sheffield), Allan Wailoo (Sheffield)</td>
<td>Fifth paper on project – reporting a study of framing effects and design considerations – published as a NICE DSU Report in Q2 2019. Four other papers already published as journal articles and/or OHE Research Papers. Koonal presented different ideas at a University of Manchester seminar in Q1 2019 and in an organised session at IHEA in July 2019.</td>
</tr>
<tr>
<td>Updated Critique of “Methods for the Estimation of the National Institute for Health and Care Excellence Cost Effectiveness Threshold”</td>
<td>Adrian Towse; Sarah Karlsberg (NHS Improvement), Jon Sussex (RAND Europe), Paul Barnsley (Policy Cures Research)</td>
<td>Dropped due to new work published by York. Proposing instead a ‘state of play’ paper by Chris Sampson, Adrian Towse and Bernarda Zamora.</td>
</tr>
<tr>
<td>Affordability/ Paying for Cures</td>
<td>Adrian Towse, Grace Marsden; various external co-authors for different parts, notably from CMPT and from ICER</td>
<td>Four papers published (see April 2018 papers). Further paper on uncertainty in ‘cures’ (authored by Adrian Towse and Liz Fenwick, Pharment) published in Value in Health.</td>
</tr>
<tr>
<td>Comparison of the availability and access to orphan medicines in 5 European countries</td>
<td>Bernarda Zamora, Phill O’Neill, Martina Garau</td>
<td>Revised manuscript accepted for publication by Orphanet Journal of Rare Diseases. Editorial published previously in the Government Gazette in 2018.</td>
</tr>
<tr>
<td>Project</td>
<td>Investigators</td>
<td>Update on progress</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Critique of CEMIPP Paper</td>
<td>Adrian Towse, Alastair Fischer (OHE Visiting Fellow)</td>
<td>Commentary on the CEMIPP Vaccines Report issued for consultation by the Department of Health (AT and AF were non-voting members of the Committee).</td>
</tr>
<tr>
<td>Long-term evaluation of broad mental health interviews</td>
<td>Chris Sampson, Alastair Canaway, (University of Warwick)</td>
<td>Delays due to change in situation for lead author. Continuation uncertain. Abandoned by lead (Canaway).</td>
</tr>
<tr>
<td>HTA and payment mechanisms for new drugs to tackle AMR</td>
<td>Olga Rozanova, Grace Hampson and Adrian Towe</td>
<td>In process for OHE publication.</td>
</tr>
<tr>
<td>Public Sector Opportunity Cost</td>
<td>Patricia Cubi-Mollá, Nancy Devlin, Martin Buxton</td>
<td>Developing links with key experts from IFS, HM Treasury, DHSE and others, by socialisation of the topic. Paper submitted to Health Policy (under review).</td>
</tr>
<tr>
<td>Blood donation in the UK. Are we doing all right? Could we do better? A comparative study with the Spanish Blood Donation context</td>
<td>Maria Errea, Grace Hampson, Marina Rodes Sanchez</td>
<td>Planned deliverable 1: literature review and discussion paper, to be published as an OHE Research Paper, and potentially submitted to a peer review journal. Planned deliverable 2: list of databases or sources which will be explored and analysed. Long-term aim is to develop an funded research proposal, for example to Public Health England and/or the NHS B&amp;T Centre.</td>
</tr>
</tbody>
</table>

**Incentivising quality**

<table>
<thead>
<tr>
<th>Project</th>
<th>Investigators</th>
<th>Update on progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variability in the probability of delayed discharge</td>
<td>Bernarda Zamora, Russell Devolder (former OHE placement student)</td>
<td>Published in Health Policy.</td>
</tr>
<tr>
<td>Maternity workforce papers</td>
<td>Graham Cookson, Bernarda Zamora, Margherita Neri, Ioannis Laliotis (LSA)</td>
<td>Currently working on 2 x OHE Research Papers. Presentations at IHEA (July) and due to be presented at HESG (January). Production function paper also presented at LSHTM seminar (October), and c-section one presented at City in December.</td>
</tr>
<tr>
<td>Regional inequalities in adiposity in England: a distributional analysis of the contribution of socio-economic position, lifestyles and the small area obesogenic environment</td>
<td>Apostolos Davillas (OHE), Andrew M. Jones (York)</td>
<td>Paper completed and is under Review at Social Science &amp; Medicine.</td>
</tr>
</tbody>
</table>
### Measuring and valuing outcomes

<table>
<thead>
<tr>
<th>Project</th>
<th>Investigators</th>
<th>Update on progress</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inequality of Opportunity in Health</strong></td>
<td>Apostolos Davillas (OHE); Andrew M. Jones (York)</td>
<td>Published in <em>Journal of Health Economics</em>. The paper also presented at the Royal Statistical Society Conference 2019, 2 – 5 September 2019, Belfast, Northern Ireland. A second working paper published recently (October 2019; <a href="https://www.iser.essex.ac.uk/research/publications/working-papers/iser/2019-09.pdf">https://www.iser.essex.ac.uk/research/publications/working-papers/iser/2019-09.pdf</a>) and published in <em>Health Economics</em>.</td>
</tr>
<tr>
<td><strong>Baseline health and public healthcare costs five years on: A predictive analysis using biomarker data in a prospective household panel</strong></td>
<td>Apostolos Davillas (OHE); Steve Pudney (Sheffield)</td>
<td>One paper published at <em>Economics and Human Biology</em> (September 2019; <a href="https://doi.org/10.1016/j.ehb.2019.100814">https://doi.org/10.1016/j.ehb.2019.100814</a>). We have published an OHE blog post to highlight the findings and policy relevance of the published paper.</td>
</tr>
</tbody>
</table>

---

**Measuring and valuing outcomes**

<table>
<thead>
<tr>
<th>Project</th>
<th>Investigators</th>
<th>Update on progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Can we really compare and aggregate PRO data between people and settings? Implications for clinical trials and HTA</td>
<td>Mike Herdman, Nancy Devlin, Paula Lorgelly (both ex-OHE); Andrea Manca (York)</td>
<td>Published as an OHE Research Paper in Q1 2019; being prepared for journal submission.</td>
</tr>
<tr>
<td>New methods for analysing the distribution of EQ-5D observations</td>
<td>B. Zamora, D. Parkin, Y. Feng, A. Bateman, M. Herdman, and N. Devlin</td>
<td>To be submitted to Medical Decision Making.</td>
</tr>
<tr>
<td>ISDR – University of Nottingham</td>
<td>Chris Sampson</td>
<td>One paper submitted (Value in Health), rejected, and resubmitted (Quality of Life Research). One paper ready for submission (Diabetes Care). Two papers are still being prepared (Diabetes Care, European Journal of Health Economics).</td>
</tr>
<tr>
<td>An online DCE study to support the development of an EQ-5D-Y value set for the UK</td>
<td>David Mott; Koonal Shah, Nancy Devlin (both ex-OHE); Oliver Rivero-Arias (Oxford), Juan M. Ramos-Góñi (Axentiva)</td>
<td>Two papers submitted to journals one on incorporating preference heterogeneity (target: Journal of Health Economics) and another comparing adult and adolescent preferences (target: Medical Decision Making). The latter has been published as an OHE Research Paper (July 2019).</td>
</tr>
<tr>
<td>The Blow of Domestic Violence on Children’s Health Outcomes</td>
<td>Melcior Rossello-Roig (University of Perugia), Mireia Jofre-Bonet and Victoria Serra-Sastre (City)</td>
<td>This paper was written with former PhD student Melcior Rossello-Roig. We are preparing to submit it to a peer reviewed journal.</td>
</tr>
<tr>
<td>Project</td>
<td>Investigators</td>
<td>Update on progress</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Falling off the cliff: The impact of Domestic Violence on Children's Educational Attainment</td>
<td>Melcior Rossello-Roig (University of Perugia), Mireia Jofre-Bonet and Victoria Serra-Sastre (City)</td>
<td>This paper was written with former PhD student Melcior Rossello-Roig. We are preparing to submit it to a peer-reviewed journal.</td>
</tr>
<tr>
<td>Children’s Well-being and Maternal Labour Supply</td>
<td>Melcior Rossello-Roig (University of Perugia), Mireia Jofre-Bonet and Victoria Serra-Sastre (City)</td>
<td>This paper was written with former PhD student Melcior Rossello-Roig. We are preparing to submit it to a peer-reviewed journal.</td>
</tr>
<tr>
<td>Uncertainty in patient trade-offs: issues in the reporting of marginal rates of substitution in discrete choice experiments</td>
<td>David Mott, Nour Chami (City), Tommi Tervonen (Evidera)</td>
<td>This is a paper arising from a MSc dissertation completed in September 2019 (Nour Chami). The paper has been published in Value in Health (August 2020)</td>
</tr>
</tbody>
</table>

### 4.2 Research Output:

Our research output falls in several categories: publications; research grants and projects; lunch-time seminars; brown-bag programme.

### 4.2.1 Publications:

We present our publications in three main groups: publications in external journals; publications on OHE’s website (peer reviewed by the OHE reviewing process); and working papers in external institutions.

#### External Journals


OHE peer-reviewed


OHE not peer-reviewed


Working papers in external sites

https://openaccess.city.ac.uk/id/eprint/22492/1/Dept_Econ_WP1912.pdf

4.2.2 Research Grants and Research Projects

Since November of 2018, OHE has won two research grants, one from IFPMA and another from the Health Foundation:

- Critique of the WHO report ‘Pricing of cancer medicines and its impacts’
  Funder: IFPMA
  OHE investigators: Simon Brassel, Olga Rozanova, Adrian Towse
  Theme(s): Judging value for money and improving decision-making
  Grant: £30,318
  OHE Income: £29,818

- Improving Labour Productivity in Primary Care: the role of skill mix, technology, and patients
  Funder: Health Foundation
  OHE investigators: Graham Cookson, Patricia Cubi-Molla, Bernarda Zamora, Margherita Neri
  External investigators: Simon de Lusignan (University of Oxford)
  Theme(s): Incentivising quality
  Grant: £499,972
  OHE Income: £286,133

OHE’s has bid for six other mostly large funding calls including the MRC and the NIHR in 2019 but we have been unsuccessful except for the grant to e-nurture for which we have been asked to resubmit the application with their input.

Funded Research projects won in 2019:

<table>
<thead>
<tr>
<th>Project</th>
<th>Project Won</th>
<th>Budget Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5060 - Thresholds in public health programs: inter and intra-country</td>
<td>06-Oct-19</td>
<td>£89,227</td>
</tr>
<tr>
<td>threshold benchmarking. Amgen AU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5086 - Critique of WHO Report IFPMA</td>
<td>01-Jan-19</td>
<td>£29,810</td>
</tr>
<tr>
<td>EE60 - EQ-SD Bolt-on Development EuroQol Research Foundation</td>
<td>01-Jan-19</td>
<td>£38,011</td>
</tr>
<tr>
<td>EE64 - Implementing Augmented Cost-Effectiveness Analysis: Challenges</td>
<td>01-May-19</td>
<td>£35,846</td>
</tr>
<tr>
<td>and Next Steps University of Washington</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EE65 – CQUINN interventions</td>
<td>01-Jan-19</td>
<td>£37,644</td>
</tr>
<tr>
<td>EE67 - MIC Part 2 Centre for Global Development</td>
<td>01-Jan-19</td>
<td>£35,099</td>
</tr>
</tbody>
</table>
Overall, independently raised funding for research in 2019 was £956,393 (research grants plus funded research projects) in 2019.

### 4.3 Lunch-time Seminars

OHE has a main programme seminar series, the lunchtime seminars, and a more informal brown-bag lunch seminar. This section provides an update on both.

**OHE LUNCHTIME SEMINARS**

Between April and end of October of 2019, there have been five OHE Lunchtime Seminars (on top of the two held between January and March, for a total of 7 from January to October 2019). The subjects range from health care system reforms, to how to measure the true value of treatments, by adjusting the measurement of improvements to specific conditions.

#### I. OHE LUNCHTIME SEMINAR: CLOSING THE ‘KNOW-DO’ GAP FOR HEALTH SYSTEMS REFORM AT THE POLICY LEVEL

Event date: Monday, 14 October 2019

OHE Lunchtime Seminar with Rafael Bengoa, Institute for Health and Strategy and David Hunter, Newcastle University entitled ‘Closing the ‘Know-Do’ Gap for Health Systems Reform at the Policy Level’.

#### II. OHE LUNCHTIME SEMINAR: HOW DO WE MEASURE THE ‘VALUE’ IN VALUE - BASED CARE?

Event date: Tuesday, 17 September 2019

Steve McKenna, Galen Research and University of Manchester. The seminar presented a model for value-based healthcare developed by Galen Research which measures outcomes in terms of patients’ fundamental needs. Under the leadership of Professor Stephen McKenna, Galen Research have developed over 30 disease-specific measures of patients’ needs, each of which has been adapted for use in over 60 countries.

#### III. OHE LUNCHTIME SEMINAR: HEALTH YEARS IN TOTAL (HYT): A NEW HEALTH OBJECTIVE FUNCTION FOR COST-EFFECTIVENESS ANALYSIS

Event date: Wednesday, 24 July 2019

In this seminar, Ariban Basu examined conceptual and theoretic arguments for use of HYT and illustrate their performance against QALYs and EVL. Methods to calculate HYT in a CEA model, to
derive CEA thresholds for HYT corresponding to the QALY-based thresholds in the US and policy implications for the use of HYT using recently published technology evaluations was also presented.

IV. OHE LUNCHTIME SEMINAR: INCENTIVES FOR R&D, COMPETITION, AND INTERTEMPORAL EFFECTS OF PAYMENT RULES FOR CURES

Event date: Thursday, 6 June 2019

Prof. Pedro Pita Barros examined how enlarging the set of possible pricing rules to those that include an intertemporal perspective can incentivise efficient investment in pharmaceutical R&D.

V. OHE LUNCHTIME SEMINAR: CASCADES OF CARE IN HEALTH POLICY ANALYSIS AND PLANNING

Event date: Monday, 29 April 2019

‘Cascades of care’ have emerged as an attractive tool for assessing access to care for numerous chronic diseases, including HIV/AIDS, addiction, diabetes, hepatitis, mental health, and tuberculosis. In this seminar Dr. Haacker discussed the use of cascades of care in health policy analysis and planning and reviewed various examples of its applications. Speaker: Markus Haacker.

4.4 Brown-Bag Programme

- Thu 25/04/2019: Grace Hampson shared her experience during her secondment at Public Health England.
- Mon 02/05/2019: Marina Rodes-Sanchez presented an update on the project PSS CQUIN schemes.
- Mon 01/07/2019: Bernarda Zamora gave a talk on her work on Reconciling ACEA and MCDA
- Tue 09/07/2019: Olga Rozanova shared her progress on the article: Can price-cap regulation increase prices?
- Thu 11/07/2019: Lauren Stewart (Goldsmith University) presented her work on Mental health in the Gambia. This presentation aimed and finding synergies with staff members at OHE for a joint grant.
- Tue 30/07/2019: Fred McElwee (intern from the University of Edinburgh) described his work on A Simulation Model for Performance-Based Risk-Sharing Agreements, done under the supervision of Lotte Steuten.
- Wed 21/08/2019: Wenrong Ye presented ‘Cost-Utility analysis of the distant-delivered mindfulness-based intervention for people with Parkinson’s Disease’, which she had written during her internship at OHE from LSE Health Policy.
- Monday 07/11/201: Amira El-Shal presented ‘Are user fees necessarily evil? Perceived quality of family planning, maternal and child health services in Egypt’.
- Wednesday 27/11/2019: Maria Errea and Dave Mott presented - Composite time trade-off
- Thursday 12/12/2019: Simon Brassel presented – Internal publication management at OHE: Process, Templates, Tips, Tricks and Knowledge exchange

4.5 OHE Annual Lecture 2019
12

The OHE Annual Lecture 2019 on 15th October was on The Evolution of U.S. Policy Responses to the Opioid Epidemic presented by Professor Richard Frank from Harvard University.

Richard G. Frank, PhD, focused on two dimensions of the U.S. response - treatment and harm reduction - placed into the larger context of the American opioid epidemic. He reviewed tools available to federal and state governments for promoting treatment and harm reduction. In particular, he directed attention to economic and regulatory policy and reviewed how they have been deployed. This includes efforts grounded in the health sector, the law enforcement system, and human services. At the end, he provided some suggestions for additional high-impact policy measures that federal and state governments could adopt.

Richard G. Frank, PhD, is the Margaret T. Morris Professor of Health Economics. His research is focused on the economics of mental health and substance abuse care, long term care financing policy, health care competition and implementation of health reform and disability policy. He served as the deputy assistant secretary for planning and evaluation at the Department of Health and Human Services (DHHS), directing the office of Disability, Aging and Long-Term Care Policy from 2009-2011. From 2014-2016, he served as the DHHS assistant secretary for planning and evaluation. Dr. Frank served as an editor for the Journal of Health Economics for nine years. He was awarded the Carl A. Taube Award from the American Public Health Association and the John Eisenberg Mentorship Award from the National Research Service Awards. He is a member of the National Academy of Medicine. He received the Academy Health Distinguished Investigator Award in June 2018.

He is co-author with Sherry Glied of the book Better but Not Well (Johns Hopkins Press). Dr. Frank received his BA in economics from Bard University and his PhD in economics from Boston University.

This 2019 OHE Annual Lecture was attended by about 200 people.

4.6 Other contributions by OHE to Research Output

Below, we list other contributions of OHE staff to research output in the form of presentations to conferences; membership to advisory boards and committees; and, impact on other researchers and policy makers.

4.6.1 External presentations by OHE staff

What follow is a list of all the presentations of OHE members of staff in conferences and other research and policy fora.
<table>
<thead>
<tr>
<th>NO</th>
<th>PRESENTATION</th>
</tr>
</thead>
</table>
| 1  | 7-9th January 2019  
Chris Sampson  
Event: HESG  
Presentation: Drop dead: is anchoring at ‘dead’ a theoretical requirement in health state valuation?  
Location: University of York, York, UK |

Numerous methodological difficulties arise from the use of ‘dead’ as an anchor in health state valuation, in particular the need to value states identified as ‘worse than dead’. The aim of this study is to explore the conceptual basis for using ‘death’ in health state valuation and to consider alternative approaches. This study has received funding from the EuroQol Research Foundation.

**RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES**

| 2  | 7-9th January 2019  
Chris Sampson  
Event: HESG  
Presentation: Discussion of paper “We now have estimates of the marginal productivity of the NHS: so what?”  
Location: University of York, York, UK |

Chris discussed this paper by Mark Sculpher and colleagues from the University of York.

**RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING**

| 3  | 7-9th January 2019  
Bernarda Zamora and Adrian Towse  
Event: HESG  
Presentation: Exploring Variations in the Opportunity Cost by Clinical Area: Results from a Feasibility Study in England  
Location: University of York, York, UK |

This paper provides further empirical evidence on the relationship between health outcomes and health expenditures in England by (1) extending the analysis to include different health outcomes, and (2) examining the relationship between mortality and health expenditures along the mortality distribution. It was discussed by David Glynn of the University of York.

**RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING**

| 4  | 7-9th January 2019  
Bernarda Zamora  
Event: HESG  
Presentation: Discussion of paper “Estimating the marginal productivity of public health care expenditure in Indonesia: a dynamic panel data approach”  
Location: University of York, York, UK |

This paper contributes to the literature by estimating the marginal productivity of public health spending in Indonesia. The main outcome is under-five and infant mortality rate, two health indicators that have exhibited significant improvements over this period.

**RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING**

| 5  | 7-9th January 2019  
Koonal Shah  
Event: HESG  
Presentation: Discussion of paper “Is aversion to inequalities in health reference-dependent? A pilot study”  
Location: University of York, York, UK |

Koonal discussed this paper by Simon McNamara and colleagues from the University of Sheffield.

**RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING**
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>This was a joint presentation by Koonal Shah and Oliver Rivero-Arias (University of Oxford). The presentation focused on the normative and practice issues associated with valuing health in children, and then presented findings from some recent empirical research. The audience comprised analysts working for NICE.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</strong></td>
</tr>
<tr>
<td>7</td>
<td>29th January 2019</td>
<td>Adrian Towse</td>
<td>Event: Duke-Margolis Meeting</td>
<td>Presentation: Exploring payment reform pathways for antibiotics from provider and payer perspectives</td>
<td>Location: Washington DC, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>As a member of the Duke-Margolis Advisory Committee on Antibiotic Incentives and Payment Reform, Adrian participated in their roundtable meeting held at the Duke-Margolis Head Office in Washing DC on January 29th.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>RESEARCH THEME(S): ECONOMICS OF INNOVATION</strong></td>
</tr>
<tr>
<td>8</td>
<td>1st February 2019</td>
<td>Amanda Cole</td>
<td>Event: Computers, Privacy and Data Protection Conference (CPDP) 2019</td>
<td>Presentation: Legal barriers to the better use of health data to deliver pharmaceutical innovation</td>
<td>Location: Brussels, Belgium</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The generation of new sources and uses of health data present significant opportunities for the pharmaceutical industry, but these are bounded by the legal context which dictates what data can be collected and how they can be used. In this presentation, I describe the nature of these legal barriers, particularly within the context of the GDPR, and propose possible solutions.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>RESEARCH THEME(S): ECONOMICS OF INNOVATION; MEASURING AND VALUING OUTCOMES</strong></td>
</tr>
<tr>
<td>9</td>
<td>4th February 2019</td>
<td>Koonal Shah</td>
<td>Event: Manchester Centre for Health Economics Seminar Series</td>
<td>Presentation: End of life treatments, societal values, and selecting a measure of ‘overall’ preference</td>
<td>Location: University of Manchester, Manchester, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Koonal gave a seminar to academic researchers based at the University of Manchester. His presentation included an overview of the evidence on public preferences regarding an end of life premium, and a discussion of how to select a measure of ‘overall’ or average preference.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</strong></td>
</tr>
<tr>
<td>10</td>
<td>7th February 2019</td>
<td>Graham Cookson</td>
<td>Event: LSHTM Health Economics Seminars</td>
<td>Presentation: Cheap &amp; Dirty: The effect of contracting out cleaning on cost and quality</td>
<td>Location: London School of Hygiene &amp; Tropical Medicine, London, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Graham gave a presentation at the LSHTM Health Economics Seminars series on the effect of contracting out cleaning on cost and quality.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>RESEARCH THEME(S): INCENTIVISING QUALITY</strong></td>
</tr>
<tr>
<td>11</td>
<td>25th February 2019</td>
<td>Graham Cookson</td>
<td>Event: UCB Patient Access, Pricing and Health Economics team visit</td>
<td>Presentation: IBP &amp; VBP: Playing to win</td>
<td></td>
</tr>
</tbody>
</table>
Graham Cookson and Adrian Towse were invited to speak to the UCB Patient Access team in Brussels. Graham’s presentation focused on concentrating UCB’s efforts on getting them to understand what their pricing strategy could be for certain drugs and to encourage them to look at steps to implement IBP and what the barriers were to success.

**RESEARCH THEME(S): ECONOMICS OF INNOVATION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7th March 2019</td>
<td>Graham Cookson</td>
<td>Orphan Drugs – High Prices: is there a way forward</td>
<td>The Royal Brompton Hospital, London, UK</td>
</tr>
</tbody>
</table>

Graham started his presentation with an introduction to orphan drugs (as relevant to respiratory medicine) and how they are appraised differently. He went on to discuss some of the problems that relate to high prices of Pharmaceuticals for orphan drugs and how they have frequently poor cost-effectiveness. And then went onto discuss how he felt that there is solution that involves a combination of real-world evidence and outcomes-based contracting.

**RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-13th March 2019</td>
<td>Koonal Shah</td>
<td>EQ-5D-Y valuation</td>
<td>Noordwijk, Netherlands</td>
</tr>
</tbody>
</table>

Koonal gave a brief presentation to EuroQol members about work that OHE had been leading on the valuation of health in children and adolescents. The presentation covered an analysis of normative issues and an overview of three empirical studies.

**RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13th March 2019</td>
<td>Chris Sampson</td>
<td>An economic perspective</td>
<td>King’s College, London, UK</td>
</tr>
</tbody>
</table>

Chris provided an overview of the relevance of economics in the context of student mental health, discussing preferences and opportunity costs. The talk was aimed at a general research audience.

**RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>19-21st March 2019</td>
<td>Lotte Steuten</td>
<td>Pay for performance: discussing the first large scale study into efficacy of the model</td>
<td>Amsterdam, Netherlands</td>
</tr>
</tbody>
</table>

Discussion on how to move value-based oncology-drug pricing discussions from ‘talk to data’. Described how we design and test, with guidance from national key opinion leaders, a value-based oncology drug pricing model suitable for evaluation in a pragmatic trial. Target audience was members of the pharma industry, payers and policy makers.

**RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>20th March 2019</td>
<td>Bernarda Zamora</td>
<td>Health Financing: Towards Universal Coverage</td>
<td>De Vere Grand Connaught Rooms, London, UK</td>
</tr>
</tbody>
</table>
Bernarda was invited to be a guest on Health Financing to achieve Universal Health Coverage for the Professional Certificate in Strategic Health Planning run by the International Centre for Parliamentary Studies. Her lecture focused on Health Financing to achieve Universal Health Coverage.

**RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>27th March</td>
<td>Adrian Towse: Exploring variations in the opportunity cost by clinical area: results from a feasibility study in England. Location: Nuffield Department of Primary Care, Oxford, UK. Adrian presented results from his study on the outcomes and health expenditures in England. <strong>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</strong></td>
</tr>
<tr>
<td>28th March</td>
<td>Grace Hampson: The Real Cost of the UK’s Poor Fruit Consumption. Location: London, UK. The purpose of this talk was to discuss the dangers and wider health/economic implications of low fruit and veg consumptions (including NHS, economy and global disease burden). <strong>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</strong></td>
</tr>
<tr>
<td>4th April</td>
<td>Koonal Shah: Directly eliciting personal utility functions. Location: Online (webinar). Koonal presented the methods and findings of an OHE-led study that developed a new approach to valuing health-related quality of life. The audience comprised health outcomes analysts working for GSK in the United States. <strong>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</strong></td>
</tr>
<tr>
<td>5th April</td>
<td>Koonal Shah: Adult versus adolescent preferences for EQ-5D-Y health states. Location: Online (webinar). Koonal discussed the normative and practical challenges involved in valuing health in children, before presenting the methods and findings of two recent EQ-5D-Y valuation studies. The audience comprised iHEA members (health economist researchers). <strong>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</strong></td>
</tr>
<tr>
<td>14th May</td>
<td>Koonal Shah: Generating preference-based values for the EQ-5D-Y to support its use in economic evaluation. Location: City University, London UK. Koonal discussed the normative and practical challenges involved in valuing health in children, before presenting the methods and findings of two recent EQ-5D-Y valuation studies. The audience comprised health economics staff and students at City University. <strong>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</strong></td>
</tr>
<tr>
<td>15th May</td>
<td>Koonal Shah: <strong>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</strong></td>
</tr>
</tbody>
</table>
| 17 | Presentation: Understanding what aspects of health and quality of life are important to people  
    Location: University of Sheffield, Sheffield UK  
    Koonal presented the methods and emerging findings of a study designed to understand what aspects of health and quality of life people in the UK and Australia consider to be important. The audience comprised health economics staff and students at ScHARR, University of Sheffield. The presentation was followed by a meeting with the E-QALY team at ScHARR to discuss the comparability of findings across the two studies.  
    **RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES** |
| 23 | **16th May 2019**  
    **Bernarda Zamora**  
    **Event: MedTech Forum 2019**  
    **Presentation: Is diagnostic information of value in health care practice?**  
    **Location: Paris, France**  
    The value of diagnostic information "VODI" concept was recently published and European organisations from different chronic and acute disease areas debates the concept and its relevance within the management of their disease. VODI is a holistic framework within Value Driven Health Systems  
    **RESEARCH THEME(S): ECONOMICS OF INNOVATION** |
| 24 | **18th May 2019**  
    **Adrian Towse**  
    **Event: ISPOR 2019**  
    **Presentation: De-risking risk sharing: Enabling payer-pharma interactions and value-based contracting with RWE.**  
    **Location: ISPOR New Orleans**  
    Engaging in value-based contracts continues to be a strategic priority among both payers and biopharmaceutical manufacturers seeking to improve health outcomes while curbing healthcare spending. However, implementation challenges exist to constructing risk-sharing agreements including (a) establishing causality between the biopharmaceutical intervention and relevant outcome (b) transparency and alignment in defining and measuring outcomes (c) enough data infrastructure to execute and track outcomes (d) assessing upfront risk due to uncertainty of real-world performance. This education symposium brought together key stakeholders — from health insurers and manufacturers to real-world data analytics providers — to describe the benefits and barriers of value-based payment models and the promising role of rapid-cycle analytics of real-world data to address these challenges.  
    **RESEARCH THEME(S): ECONOMICS OF INNOVATION** |
| 25 | **20th May 2019**  
    **Lotte Steuten**  
    **Event: ISPOR 2019**  
    **Presentation: The clinical and economic value of genetic sequencing in cancer care: are next generation sequencing (NGS)-based tests clinically useful and cost effective in real world settings? What is necessary to fully realize their value?**  
    **Location: New Orleans, USA**  
    This panel debated the value proposition for the use of NGS-based Dx testing for cancer care using aNSCLC as an example. Lotte moderated the panel and provided an overview of the current landscape of evidence of clinical and cost effectiveness of NGS testing in aNSCLC and posed key questions for the panelists to debate.  
    **RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING** |
| 26 | **20th May 2019**  
    **Lotte Steuten**  
    **Event: ISPOR 2019**  
    **Presentation: ISPOR Open-Source Models Special Interest Group: Lies, damned lies and cost-effectiveness** |
Cost-effectiveness and disease models are often statistically sophisticated and may be seen as opaque by stakeholders [1]. Open-source models (OSM) would encourage greater transparency and facilitate the reuse and updating of the best/most useful models. Per ISPOR-SMDM and EUnetHTA, OSM advanced modelling methods by reducing bias, increasing transparency, improving model access, and allowing for faster access to critical knowledge. With openness and sharing come issues of copyright and access and a need to define how model sharing can be achieved in an equitable manner. The pros and cons of OSMs and the proposed mission of the Open Source Model SIG was debated amongst SIG members.

**RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>21st May 2019</td>
<td>Adrian Towse</td>
<td>Real option value for drugs: is it really an option?</td>
<td>New Orleans, USA</td>
</tr>
</tbody>
</table>

The ISPOR US Task Force report recommended exploring additional elements of value for inclusion in value assessment of new drugs. One of these was Real Option Value. This panel debated whether and how it could be done, and if this is a good idea.

**RESEARCH THEME(S): ECONOMICS OF INNOVATION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>21st May 2019</td>
<td>Adrian Towse</td>
<td>MCDA or weighted CEA based on the QALY? which is the future for HTA decision making?</td>
<td>New Orleans, USA</td>
</tr>
</tbody>
</table>

This panel discussed whether we should continue to use (and improve) cost-effectiveness analysis as the primary method for technology evaluation or move to (and improve) multi-criteria decision analysis models?

**RESEARCH THEME(S): ECONOMICS OF INNOVATION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>23rd May 2019</td>
<td>Mireia Jofre-Bonet</td>
<td>Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in Sweden and the UK: The Case of Risperidone</td>
<td>London, UK (attended remotely via video)</td>
</tr>
</tbody>
</table>

This is an annual event hosted by NHS England and NHS Improvement. Mireia was invited to discuss careers in economics.

**RESEARCH THEME(S): NONE APPLY**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12-14th June 2019</td>
<td>Bernarda Zamora</td>
<td>Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in Sweden and the UK: The Case of Risperidone</td>
<td>Albacete, Spain</td>
</tr>
</tbody>
</table>

This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their lifecycle in the UK and Sweden. It concludes that considering the entire lifecycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider the value added by medicines over the long run.

**RESEARCH THEME(S): ECONOMICS OF INNOVATION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12-14th June 2019</td>
<td>Marina Rodes Sanchez</td>
<td>Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in Sweden and the UK: The Case of Risperidone</td>
<td>Albacete, Spain</td>
</tr>
</tbody>
</table>
### 19

**Presentation:** The introduction of pay for performance for specialised care in England  
**Location:** Albacete, Spain

Prescribed Specialised Services (PSS) Commissioning for Quality and Innovation (CQUIN) schemes were launched in 2013 in England with the aim of improving the quality of specialised care and achieving value for money. During this presentation, Marina described the key features of the schemes and discussed its strengths and weaknesses based on international pay-for-performance literature. The session was organized by Patricia, joint with Laia Maynou (London School of Economics), on behalf of the special interest group on the evaluation of health policies and health care services (EvaluAES).  

**Research Theme(s):** Economics of Innovation

### 32  
**12-14th June 2019**  
**Patricia Cubi-Molla**  
**Event:** XXXIX Jornadas de Economía de la Salud (AES Conference)  
**Presentation:** Outcome-based payment schemes: what outcomes do cancer patients value?  
**Location:** Albacete, Spain

Patricia presented the main results of a project funded by Cancer Research UK with Greater Manchester Health & Social Care Partnership, on making outcome-based payments a reality in the NHS.  

**Research Theme(s):** Measuring and Valuing Outcomes

### 33  
**12-14th June 2019**  
**Maria Errea**  
**Event:** XXXIX Jornadas de Economía de la Salud (AES Conference)  
**Presentation:** Blood donation in the UK. Are we doing all right or could we do better?  
**Location:** Albacete, Spain

Blood is collected in the UK through voluntary (not remunerated) human donations. The number of appointments booked with NHS Blood and Transplant (NHSBT) has significantly risen in recent years. However, evidence shows that the number of appointments is greater than the number of final blood donations. Given that there is an urgent need for more blood donors, NHSBT is interested to explore the key factors that are driving potential donors who book an appointment to make a blood donation (or not). The aim of this project is to explore the circumstances and characteristics that lead to a donation, compared to those that do not lead to a donation, amongst people who book an appointment. In this poster presentation, Maria discussed previous research showing that campaigns have an impact on the number of new blood donors and consider data on the number of new donors per day compared with the level of demand in NHSBT.  

**Research Theme(s):** Incentivising Quality

### 34  
**12-14th June 2019**  
**Maria Errea**  
**Event:** XXXIX Jornadas de Economía de la Salud (AES Conference)  
**Presentation:** Experiencia docente en la organización y gestión de servicios sanitarios  
**Location:** Albacete, Spain

Maria contributed to a discussion of experiences in delivering a postgraduate course – launched two years ago – for current professionals of the health care system who want to become managers of a health organisation. The presentation was about the experience of teaching to a very particular group of students, most of whom work full time at a hospital or ambulatory health care centre, and about the organisation of the modules.  

**Research Theme(s):** Judging Value for Money and Improving Decision-Making

### 35  
**12-14th June 2019**  
**Marina Rodes-Sanchez**  
**Event:** XXXIX Jornadas De Economia De La Salud (Aes Conference)  
**Presentation:** The introduction of pay for performance for specialised care in England  
**Location:** Albacete, Spain

**Research Theme(s):** Judging Value for Money and Improving Decision-Making
<table>
<thead>
<tr>
<th>No.</th>
<th>Date</th>
<th>Name</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
<th>Research Theme(S):</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>36</td>
<td>15th June 2019</td>
<td>Mikel Berdud</td>
<td>HTAi 2019</td>
<td>Quantifying the Life-cycle Value of Innovative Medicines: The Case of Risperidone</td>
<td>Cologne, Germany</td>
<td>Judging Value for Money and Improving Decision Making; Economics of Innovation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>17th June 2019</td>
<td>Lotte Steuten</td>
<td>HTAi 2019</td>
<td>Health-economic modelling to inform private sector investment in tuberculosis</td>
<td>Cologne, Germany</td>
<td>Judging Value for Money and Improving Decision Making</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>treatment for middle-income countries</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>17-19th June 2019</td>
<td>Margherita Neri</td>
<td>HTAi 2019</td>
<td>Adapting HTA and Procurement to tackle antimicrobial resistance</td>
<td>Cologne, Germany</td>
<td>Judging Value for Money and Improving Decision Making</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>20th June 2019</td>
<td>Mireia Jofre-Bonet</td>
<td>Graduating Class for the master’s in economics and Business Administration 2019</td>
<td>N/A</td>
<td>Universitat Autònoma de Barcelona, Barcelona, Spain</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>24th June 2019</td>
<td>Lotte Steuten</td>
<td>Roche Meeting</td>
<td>Value assessment of tumour-agnostic therapies: co-creating market access and HTA roadmaps</td>
<td>Brussels, Belgium</td>
<td>Judging Value for Money and Improving Decision Making</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>24-25th June 2019</td>
<td>Grace Hampson</td>
<td>Challenges in the Adoption of Regenerative Therapies Workshop</td>
<td>Health Economics (Discussant)</td>
<td>Toronto, Canada</td>
<td>Judging Value for Money and Improving Decision Making</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A presentation of a research by a team of OHE and IHE researchers that estimates the value added by second generation antipsychotics over their lifecycle in the UK and Sweden.

The research concludes that considering the entire lifecycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider the value added by medicines over the long run.

RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING; ECONOMICS OF INNOVATION

There is growing recognition that HTA and contracting systems for antimicrobials need to be adapted to help fight the threat of antimicrobial resistance (AMR), but there is little agreement on how. This poster reports findings from a literature review, expert interviews, and face-to-face discussions at a Forum on the current HTA and payment systems for antibiotics across Europe and recommendations for adapting these systems to respond to the challenges of AMR.

RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING

Mireia presented in front of graduating master’s in economics and Business Administration students at her alma mater, Universitat Autònoma de Barcelona.

RESEARCH THEME(S): NONE APPLY

Discussing presentation on how to evaluative the cost-effectiveness of regenerative medicines, the challenges and experience to date.
<table>
<thead>
<tr>
<th>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</th>
</tr>
</thead>
</table>
| 42 | 24-25\(^{th}\) June 2019  
Grace Hampson  
Event: Challenges in the Adoption of Regenerative Therapies Workshop  
Presentation: Payment system mechanisms (Discussant)  
Location: Toronto, Canada |
|  | Discussing presentation on the available payment mechanisms, whether they are necessary, and how they could be implemented. |

<table>
<thead>
<tr>
<th>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</th>
</tr>
</thead>
</table>
| 43 | 28\(^{th}\) June 2019  
Chris Sampson  
Event: London Visual Impairment Forum  
Presentation: N/A  
Location: Thomas Pocklington Trust, London, UK |
|  | Chris introduced the use of the EQ-5D in research and decision-making and an overview of our EQ-5D Bolt-ons project. |

<table>
<thead>
<tr>
<th>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</th>
</tr>
</thead>
</table>
| 44 | 28\(^{th}\) June 2019  
Mireia Jofre-Bonet  
Event: Masterclass for policy makers and the pharma industry  
Presentation: Introduction to Economic Evaluation  
Location: Universitat International de Barcelona, Barcelona, Spain |
|  | Mireia spoke at a recent masterclass, supported by Celgene, on economic evaluation for policy makers and the pharma industry. |

<table>
<thead>
<tr>
<th>RESEARCH THEME(S): JUDGING VALUE FOR MONEY</th>
</tr>
</thead>
</table>
| 45 | 2\(^{nd}\) July 2019  
Lotte Steuten  
Event: Lilly GPORWE International Lilly  
Presentation: The delivery of scientific evidence for the evaluation of medicines throughout their lifecycle  
Location: Surrey, UK |

<table>
<thead>
<tr>
<th>RESEARCH THEME(S): ECONOMICS OF INNOVATION</th>
</tr>
</thead>
</table>
| 46 | 3-5\(^{th}\) July 2019  
Bernarda Zamora  
Event: HESG Summer 2019  
Presentation: Reconciling ACEA and MCDA: Is There a Way Forward for Measuring Cost-Effectiveness in the U.S. Healthcare Setting  
Location: Norwich, UK |
|  | We explore the idea of what could be called a "QALY-anchored" MCDA and compared with a form of Augmented ECA where elements of value are either classified as health or consumption attributes— and ultimately monetised. |

<table>
<thead>
<tr>
<th>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</th>
</tr>
</thead>
</table>
| 47 | 13-17\(^{th}\) July 2019  
Mikel Berdud  
Event: IHEA world Congress on Health Economics 2019New Heights in Health Economics  
Presentation: Quantifying the Life-Cycle Value of Innovative Medicines: The Case of Risperidone and Second-Generation Antipsychotics  
Location: University of Basel, Basel, Switzerland |
|  | Mikel’s Presentation discussed why the life-cycle value of new medicines should be considered to balance the view that cost per QALY estimates at launch are enough to guide access decisions. Research results presented showed that value added by medicines changes over the life-cycle. |
changes in response to the launch of improved and superior presentations, generic competition and new indications. The target audience of this research is composed by policy makers, payers, HTAs (e.g., NICE, SMS), industry and academic researchers interested in the themes of judging value for money and improving decision making and/or Economics of Innovation.

**RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING; ECONOMICS OF INNOVATION**

<table>
<thead>
<tr>
<th>Event</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15th July 2019</td>
<td>Graham Cookson</td>
<td>Basel, Switzerland</td>
</tr>
<tr>
<td>16th July 2019</td>
<td>Graham Cookson</td>
<td>Basel, Switzerland</td>
</tr>
<tr>
<td>13-17th July 2019</td>
<td>Koonal Shah</td>
<td>Basel, Switzerland</td>
</tr>
<tr>
<td>23rd August 2019</td>
<td>Mireia Jofre-Bonet</td>
<td>London, UK</td>
</tr>
<tr>
<td>3-5th September 2019</td>
<td>Apostolos Davillas</td>
<td>Basel, Switzerland</td>
</tr>
</tbody>
</table>
Presentation: A latent class approach to inequity in health using biomarker data
Location Belfast, Ireland

This was an honorary/invited presentation/talk that discussed how to develop an empirical approach to analyse, measure, and decompose Inequality of Opportunity (IOp) in health, based on a latent class model. The presentation addressed the limitations that affected earlier work concerning the definition of types—such as partial observability, the ad hoc selection of circumstances, the curse of dimensionality and unobserved type-specific heterogeneity—that may lead to either upwardly or downwardly biased estimates of IOp. They applied the latent class approach to quantify IOp in allostatic load, a composite measure of our biomarker data. Using data from Understanding Society (UKHLS), we find that a latent class model with three unobserved types best fits the data and that these types differ in terms of their observed circumstances. Decomposition analysis shows that about two-thirds of the total inequality in allostatic load can be attributed to the direct and indirect contribution of circumstances.

RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES

54 18-21st September 2019
David Mott
Event: EuroQol Plenary Meeting
Presentation: What aspects of health and quality of life are important to people? Existing health and quality of life measures are often considered to be too narrow.
Location: Brussels, Belgium,

This work explores the aspects of health and quality of life that matter to people, with a view to exploring how a new generic measure might look if built from the ‘bottom up’. The methodology and results are of particular interest for studies that set a patient-centred framework. Shah, K.K., Mulhern, B., Cubi-Molla, P., Janssen, B., and Mott, D.J. 2019. “What aspects of health and quality of life are important to people?”

EuroQol grant 2016370 Collaborators: Koonal Shah, Louise Longworth (PHMR) Brendan Mulhern (University of Technology Sydney) John Brazier (University of Sheffield) Nancy Devlin (University of Melbourne) Bas Janssen (Erasmus University) Nan Luo (National University of Singapore)

RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES

55 23-24th September 2019
Mireia Jofre-Bonet
Event: IV Expert Programme in Health Policy and the Economics of the Pharmaceutical Sector
Presentation: Does the current approach of economic evaluation promote R&D in the pharmaceutical industry?
Location: Palma de Mallorca, Spain

Mireia was invited to give a talk about economic evaluation and R&D in the pharma industry at the IV Expert Programme in Health Policy and the Economics of the Pharmaceutical Sector in Mallorca, Spain. In Mireia’s presentation she discussed the pros and cons of the present HTA/CEA framework for innovation in the pharmaceutical sector in the UK. The panel discussion was based on their experience in different countries.

RESEARCH THEME(S): JUDGING VALUE FOR MONEY

56 23rd September 2019
Bernarda Zamora
Event: NIHR London IVD Co-operative
Presentation: Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics
Location Imperial college London

Bernarda gave a Lecture on how to value diagnostics information and the novel elements of value

RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING

57 26th September
Patricia Cubi-Molla
<table>
<thead>
<tr>
<th>Event: GSK IMAPRO Meeting</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation: Health valuation, age, and experience</td>
<td></td>
</tr>
<tr>
<td>Location: Webinar</td>
<td></td>
</tr>
<tr>
<td>Patricia presented a number of pieces of research she undertook in the past year.</td>
<td></td>
</tr>
<tr>
<td>• A note on the relationship between age and health-related quality of life assessment</td>
<td></td>
</tr>
<tr>
<td>• Experience-based values: a framework for classifying different types of experience in health valuation research</td>
<td></td>
</tr>
<tr>
<td>• How experience affects the valuation of EQ-5D profiles: a revision of the UK tariffs using a fixed effects model (working paper, unpublished)</td>
<td></td>
</tr>
</tbody>
</table>

**RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES**

<table>
<thead>
<tr>
<th>Event: LSTHM</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation: A Production Function for Maternity Services in the English NHS</td>
<td></td>
</tr>
<tr>
<td>Location: London</td>
<td></td>
</tr>
<tr>
<td>This paper analyses the role of medical and non-medical staff in the production of maternity services in the English NHS. Using hospital panel data (2004-2012) and estimating flexible production functions using system GMM estimators, we explore the output contribution of maternity services labour inputs. The results suggest that consultants and doctors have the highest marginal productivities while the productivity of support workers is insignificantly different from zero. Moreover, there is evidence for some degree of complementarity between midwives, support workers and consultants. Moreover, midwives could replace doctors and doctors could replace consultants in the production of maternity services.</td>
<td></td>
</tr>
</tbody>
</table>

**RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES**

| Event: Orphan Drugs and Rare Diseases conference |  |
| Presentation: MoCA early dialogue between payers and manufacturers: An Opportunity to Improve Decision Making for Orphan Drugs in Europe? |  |
| Location: London |  |
| Orphan drugs inherently face a number of challenges in their development and value assessment. In my presentation, I describe the Mechanism of Coordinated Access (MoCA) initiative and discuss why it can be beneficial to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries. |  |

**RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING**

| Event: ISPOR Europe 2019: |  |
| Presentation: Is indication-based pricing feasible and/or beneficial for society? |  |
| Location: Copenhagen |  |
| Chair: Mireia Jofre-Bonet OHE |  |
| Participants: |  |
| Andrew Briggs LSHTM |  |
| Adrian Towse OHE |  |
| Francis ARYCKS, National Institute Health & Disability Insurance, Belgium |  |
| Mireia introduced the subject of whether the IBP is beneficial to society or not, with a few PROS and CONS and lead the discussion afterwards. |  |

**RESEARCH THEME(S) ECONOMICS OF INNOVATION**

| Event: 4th November 2019 |  |
| Patricia Cubi-Molla |  |
This research explores the feasibility of introducing an Outcome-Based Payment approach for new cancer drugs in England. A literature review explored the current funding landscape in England, the available evidence on existing OBP schemes internationally, and which outcomes cancer patients value most. Two focus groups and an online survey with patients and carers, as well as interviews with NHS and government stakeholders, healthcare professionals, and pharmaceutical industry representatives, provided additional evidence on the feasibility and suitability of OBP schemes.

**RESEARCH THEME(S):** MEASURING AND VALUING OUTCOMES; JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING

**Poster: Making outcome-based payment a reality in the national health service for England**

**Location:** Copenhagen, Denmark

We report the results of a consultation where we sought the insight of different stakeholders (industry, payers, regulators, and academics) from across different European countries, on the relative merits of IBP and issues around its implementation. Funded by AstraZeneca (832)

**RESEARCH THEME(S):** JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING; INCENTIVISING QUALITY

**Poster: Should drug prices differ by indication? Results of a consultation.**

**Location:** Copenhagen, Denmark

We report an interim evaluation of population rollout of Sleepio, estimating the change in primary care costs. Using an interrupted time series analysis, we show a small shift to a downward trend in primary care costs. Oxford AHSN (823)

**RESEARCH THEME(S):** JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING

**Presentation: Development of EQ-5D-5L bolt-ons for cognition and vision**

**Location:** Copenhagen, Denmark

We report on a series of qualitative focus groups and interviews to identify the domains and terminology for two EQ-5D bolt-ons. The findings inform qualitative and quantitative testing of candidate bolt-on descriptors.

**Research theme(s) Measuring and valuing outcomes**

**Presentation: Health valuations, age, and experience, Module: ECM163 Economic Evaluation**

**Location:** London, UK

Patricia gave a lecture/seminar to students of MSc Economic Evaluation in Health care and MSc Health Economics. The slides put together material form a number of pieces of research I undertook last year:

- A note on the relationship between age and health-related quality of life assessment
- Experience-based values: a framework for classifying different types of experience in health valuation research
- How experience affects the valuation of EQ-5D profiles: a revision of the UK tariffs using a fixed effects model (working paper, unpublished)

**RESEARCH THEME(S) MEASURING AND VALUING OUTCOMES**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>19th Nov</td>
<td>Simon Brassel</td>
<td>A presentation and Q&amp;A session to students with an interest in a career in health economics/health policy</td>
<td>London, London School of Economics</td>
</tr>
<tr>
<td>21 Nov</td>
<td>Mireia Jofre-Bonet</td>
<td>Attended Steering Group meeting for the SUPERB trial: member of the Steering Group for this grant on supporting people after stroke using buddies. It is funded by the STROKE foundation. Yes, you can publish it.</td>
<td>Location: London, member of the Steering Group for this grant on supporting people after stroke using buddies. It is funded by the STROKE foundation. Yes, you can publish it.</td>
</tr>
<tr>
<td>26-27 Nov</td>
<td>Mireia Jofre-Bonet</td>
<td>The trial is called: Adjustment with aphasia after stroke: Supporting wellbeing through PEEr Befriending (SUPERB), funded by the Stroke Association.</td>
<td>Location: London, member of the Steering Group for this grant on supporting people after stroke using buddies. It is funded by the STROKE foundation. Yes, you can publish it.</td>
</tr>
<tr>
<td>6th Dec</td>
<td>Graham Cookson</td>
<td>Graham gave a presentation at City Health Economics Centre, he first presented trends in maternity services in the English NHS before presenting research on two topics: (i) the role of staffing levels and skill mix on provider efficiency, and (ii) the impact of staffing and skill mix on the rate of Caesarean sections</td>
<td>Location: London, City Health Economics Centre, he first presented trends in maternity services in the English NHS before presenting research on two topics: (i) the role of staffing levels and skill mix on provider efficiency, and (ii) the impact of staffing and skill mix on the rate of Caesarean sections</td>
</tr>
<tr>
<td>5th Dec</td>
<td>Chris Sampson</td>
<td>My presentation provided a critical response to the threshold proposed by Mike Paulden for the identification of cost-effectiveness thresholds. The framework has been used in Canada.</td>
<td>Location: London, City Health Economics Centre, he first presented trends in maternity services in the English NHS before presenting research on two topics: (i) the role of staffing levels and skill mix on provider efficiency, and (ii) the impact of staffing and skill mix on the rate of Caesarean sections</td>
</tr>
</tbody>
</table>
Advisory roles held by OHE staff members

The number of advisory roles of OHE staff members has continued growing and reflects the good standing of OHE members in terms of impacting in policy and being able to judge valuable research. Having impact and helping steer health policy and decision making in health economics is an essential OHE charitable object.
OHE staff membership of advisory panels, boards and committees

1. NICE: Public Health Guidelines Standing Committee – Grace Hampson
2. NICE: Member of the Expert Advisers Panel for the Centre for Guidelines – Mireia Jofre-Bonet
3. IHEA: Special interest group on the economics of obesity – Grace Hampson
4. IHEA: Member of the 'health systems' efficiency' interest group – Margherita Neri
5. IHEA: Programme Chair Scientific Committee on Production of Health, Health Behaviours & Policy – Apostolos Davillas
6. ISPOR: Value Frameworks Special Task Force – Adrian Towse
7. ISPOR: Board of Directors Past President – Adrian Towse
8. ISPOR: Rare Disease Special Interest Group Member – Graham Cookson
9. ISPOR: Oncology Special Interest Group Member – Graeme Cookson
10. ISPOR: Statistical Methods in Health Economics and Outcomes Research Special Interest Group Member – Graham Cookson
11. ISPOR: Member of the ‘Value of Information’ Task Force – Lotte Steuten
12. ISPOR: Health Preference Research Group Member – David Mott
13. EvaluAES (supported by the Spanish Health Economic Association): Co-ordinator of special interest group on the evaluation of health policies and health care services – Patricia Cubí-Mollá
14. EvaluAES (supported by the Spanish Health Economic Association): Member of special interest group on the evaluation of health policies and health care services – Maria Errea
15. EuroQol Group: Executive Committee – Koonal Shah
16. NIHR: Steering Committee Member for NIHR/HS&DR Project No. 8/17/1934 – Graham Cookson
17. NIHR – Member of a Study Steering Committee (SSC) for the LOGIC (Longitudinal Outcomes of Gender Identity in Children) project – Mireia Jofre-Bonet
18. MRC: Advisory group for Extending the QALY project – Koonal Shah
19. UK Pharmacogenetics & Stratified Medicine Network: Member – Bernarda Zamora
20. Health Foundation: Steering Committee Member for NHS Workforce Retention Project – Graham Cookson
21. Scientific Experts and Methodologists Group (SEM) Delphi Panel Member of the IMPACT-HTA (WP7) project “Improved methods and actionable tools for enhancing HTA” – Martina Garau
22. EuroQol Group: Executive Committee – Koonal Shah
23. International Health Economics Association Scientific Committee - Program Chair – Production of Health-Health Behaviours & Policy-Renewed for the 2019-2021 - Apostolos Davillas
24. Member of the Steering Group of the Early Diagnosis Research Alliance – Bernatda Zamora

Visiting positions for OHE staff

1. School of Health and Related Research, University of Sheffield – Honorary Research Fellow – Koonal Shah
2. London School of Economics – Visiting Professor – Adrian Towse
3. Nuffield Department of Population Health, University of Oxford – Senior Visiting Fellow – Adrian Towse
4. Oxford University Hospitals NHS Trust – Honorary Health Economist – Amanda Cole
5. Oxford University Hospitals NHS Trust – Honorary Health Economist – Chris Sampson
6. Public University of Navarra and The Navarra’s Health System – Invited Lecturer on Management and Organization of Health Care Services – Maria Errea
7. Public University of Navarra – Visiting Researcher – Mikel Berdud
8. University of Surrey – Visiting Professor – Graham Cookson
9. Science Policy Research Unit, University of Sussex – Associate Faculty Member – Grace Hampson
10. City, University of London – Honorary Visiting Professor – Lotte Steuten
11. City, University of London – Honorary Visiting Professor – Graham Cookson
12. City, University of London – Professor, Department of Economics – Mireia Jofre-Bonet
13. City, University of London – Honorary Senior Research Fellow – Patricia Cubi-Mollá
15. University of Essex – Research Fellow: Institute for social and Economics Research – Apostolos Davillas
16. Fred Hutch Cancer Research Center, University of Washington – Affiliate Investigator – Lotte Steuten
17. University of East Anglia – Honorary Senior Fellow – Chris Skedgel

4.6.3 Examples of OHE’s impact

In 2019, OHE’s work has continued to have a remarkable impact. Below, we list those we have a record of:

Citations of OHE research by decision-makers, policy influencers and the media

- The OHE Research Paper 'Making Outcome-Based Payment a Reality in the NHS' was cited in a press release by Cancer Research UK. It was also cited by commentators and media outlets such as Pharmatimes, Pharmafield, PMLive, The Pharma Letter, Royal College of Nursing, Health Innovation Manchester, and Medscape. The Medscape article included a quote from NICE welcoming the publication of the paper.
- OHE’s Brexit analysis was cited in the Government impact assessment on the implications of setting up the MHRA as a standalone UK regulator. As a result, it was referenced in articles in The Times and Politico. OHE's report on Brexit was also cited in an article on PMLive.
- The business and technology news website xconomy.com featured an article about the OHE and ICER white paper on models for pharmaceutical rebates. An article on the white paper was also published in The Pharma Letter.
- The Center for Global Development recently published a critique of the World Health Organization’s technical report on cancer drug pricing. The critique was co-authored by Adrian Towse. Politico Europe named both Adrian and OHE in their health care briefing on the topic.
- NICE expressed interest in OHE’s work on valuing health in children, and invited Koonal Shah to present at a NICE Technical Briefing in March 2019. The event was attended by over 40 analysts, and members of NICE’s Science and Policy Research team organised internal follow-up discussions to reflect on the issues raised and further meetings with OHE to take the research agenda forward. See here for an OHE blog on this presentation.

Impact on the research of others

In February 2019, a Senior Economist at the Department of Health and Social Care received a request for information on NHS expenditure on branded medicines from a professor of law at Suffolk
University Law School in the US. He responded by referring the requestor to OHE’s research on NHS expenditure.

In February, Fabia Gansen of the University of Bremen got in touch with Koonal Shah to advise him that she is working on a programme of research that builds on and is inspired by OHE’s research on ‘personal utility functions’.

Advice sought from OHE
There are numerous cases of advice sought from OHE, as an example, in March 2019, Graham Cookson and Koonal Shah provided a small amount of pro bono advice to policy advisers at the Treasury (following a request for advice/information) regarding the value of QALYs.

5 Research Plans for 2020

5.1 General Research Strategy

As explained above, at the end of last year, researchers at OHE identified 5 research topics for each of the four research themes which they thought would generate most research interest in the year 2020 and beyond. The selected top 5 topics per theme were to be sent to key researchers and stakeholders for an indicative vote for the one topic under each theme that they believe was going to be most salient in 2020. This strategic exercise, which we called Top 20 Research Topics for 2020, had the objective of getting a sense of what key individuals believed were going to be the top-priority areas of knowledge in the near future. This information was presented to the Research Committee in January 2020, which provided very valuable feedback on the interest and ultimate relevance of some of these themes to the team.

OHE’s primary research objective for 2020 was and still is to significantly, but sustainably, grow our external research funding by adopting the following strategies:

1. Future Leaders: to develop future research leaders within OHE and increase the number of staff acting at Principal Investigator level to share the burden of increasing our research funding more broadly. We are investing in supporting the next generation of research leaders within our organisation, by increasing their profile, establishing more structured/periodic communication channels to stimulate and catalyse activity, while offering an enhanced research environment

2. Alignment: we are developing a more efficient and systematic approach to identify, select, and respond to funding calls. The intention is to be able to better align OHE’s proposals to funders’ sought-after topics. This should enable OHE to balance funded research across research themes

3. Efficiency: we want to improve the time we spend on writing applications and to increase the average length and value of research grants we apply for. As part of this effort, we intend to systematically explore potential patterns in successful and failed grant applications to increase our success rate

The secondary research objective is to continue to improve the research environment of OHE, and we have several strategies to achieve this goal:

1. Launch an OHE Annual Conference
2. Expand the number of OHE Visiting Fellows (including Visiting Policy Fellows) and deepen these and existing relationships
3. **Enhance the training opportunities and programmes** (we have started a OHE-MSc in Health Economics Fellowship at City and are aiming to find funding for a PhD in the Micro-economics and Econometrics of the Pharmaceutical Industry)

4. Define and develop our partnership with City, University of London, as well as other universities

Internally, we planned to develop our research strategy in the following manner:

- Each theme to hold a **theme quarterly meeting** chaired by the theme lead and attended by OHE staff interested in that theme. Potential funding opportunities, research ideas and activities to be discussed and agreed upon
- Theme leads to meet with the Head of Research **quarterly** to discuss the development of research topics and research issues of general interest that are relevant to all themes
- We are considering starting a **Lunch-time Journal Club** to debate recent articles and/or novel ideas in health economics. One possibility is to draw from our colleague Chris Sampson’s blog *THE ACADEMIC HEALTH ECONOMISTS’ BLOG’*
- We are considering whether to create a **Specialist Digital Seminal Papers’ Library** on particular topics in health economics. This library would be both a tool to do research but also a means for staff to learn about especial health economics research topics, independently
- We are planning to re-visit the possibility to **improve direct access to Digital Libraries**, to avoid relaying on individual access to universities with which individual staff are affiliated
- We are continuing to **develop and systematise the information on forthcoming funding calls** – e.g. updating our file based on main funders (MRC, NIHR, Gates Foundation) and/or coordinating with the research office of the Health Sciences department of City, University of London
- Explore, agree, and put in place a **OHE open access policy** for OHE research output. At the suggestion of our colleague, Chris Sampson, in 2020 opportunities for OHE to commit to more transparent research practices to be investigated as well as the potential value to OHE of committing to initiatives such as open access publication and open data, along with considering the development of repositories and internal mandates and policies to support these.

### 5.2 Research Plans by Theme and Presentation by Leads

As objectives for all themes in 2020, OHE agreed that:

- each theme aims to submit at least **one research grant** relating to their top research topics
- each theme to organise at least one **Lunchtime Seminar** to establish contact and explore collaborations with experts that can be relevant for joint grant submissions for one of the 2020 topics for each research theme or other research projects. While the content of the presentation may be different to the 2020 topic, this should enable the team to explore common topic interests
- each theme to organise a panel session at the **OHE 2020 Conference** related to one of their 2020 top topics
• Theme leads aim to blog on their themes’ research hot topics. The purpose is to use the OHE’s blog strategically to ‘make noise’ and attract attention to the topic, generating potential new research collaborations.

In the following section, we present the updated research plans for 2020 by Theme. Additionally, each theme leader to lead a short discussion of their research goals in the next year.

Judging Value for Money and Improving Decision-Making (Martina Garau)

Main topic

The role of the cost effectiveness threshold in HTA decision making to implement value-based pricing seems to be recognised in an increasing, QALY-driven, number of countries (both high-and middle-income). For example, there is a proposal in Canada to introduce an explicit threshold to set prices at product launch. Traditionally, OHE work on thresholds has been commissioned by UK funders and has helped informed the academic and policy debate in the UK.

Giving the growing importance in other contexts, we would value suggestions from the Committee on how to explore new sources of funding outside the UK around the topic of cost effectiveness thresholds and their role in funding decisions.

Other key topics for 2020

• Interest in multi-attribute frameworks in the US and other geographies is expected to continue. Related key areas identified as important to explore are the development of robust methods for aggregation (going beyond a simple definition of a list of elements of value) and the generation of evidence on societal and patient preferences to inform decision-making.
• Continuing exploring the issues related to the assessment and separation of value of interventions to use jointly (e.g. combination therapies, and companion diagnostic and treatment).

The Research Away Day 2019 was a good opportunity to identify the key hot topics that we might want to explore in 2020. Feedback on the five selected is very welcome. The list that emerged is:

HOT TOPICS IN 2020:

<table>
<thead>
<tr>
<th></th>
<th>Judging value for money / structured decision making</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Developing good practice in HTA: What is the optimal model for reimbursement decision-making in different contexts?</td>
</tr>
<tr>
<td>2</td>
<td>Cost-effectiveness and treatment pathways: How can evidence of value be incorporated into clinical decision-making?</td>
</tr>
<tr>
<td>3</td>
<td>Understanding opportunity costs: How can we reconcile expanded concepts of value and displacement?</td>
</tr>
<tr>
<td>4</td>
<td>Real-world evidence and data systems: Can digital systems support decision-making?</td>
</tr>
<tr>
<td>5</td>
<td>Multi-sectoral resource allocation: How should resource allocation be managed beyond health and health care?</td>
</tr>
</tbody>
</table>
Main objective for 2020

Given the sources of income of this theme, it appears to be responding to private for-profit funders’ demand. Thus, the stream of consulting work is very healthy but there might be a need to rebalance towards research. The theme lead indicated that ideally the number of peer review publications and independent research ought to increase to achieve this. To achieve this objective in 2020 it is crucial to set a research grants application strategy as well as to work in external research collaborations, in particular, with academics and universities, but also with other research institutions (e.g., consultancies, think-tanks, charities)

Main topic
Main topics
In terms of being proactive, the team identified two main research areas of interest for this theme:

First, subjects related to:
- Price transparency
- Indication based pricing
- Outcomes based pricing
- Combination therapy pricing
- Paying and pricing cures
- Value-based pricing of cancer drugs
- Global health and NTD
- Alternative models of rebates
- Regulation and incentives for OMPs
- Competition and regulation: tendering
- Open innovation
- Adaptive pathways
- Real-world evidence
- Health systems barriers

Second, the team perceived that the market itself demands research in the following subjects:
- Indication based pricing
- Price transparency
- Combination therapy pricing
- Paying and pricing cures
- Competition and regulation: tendering
- Regulation and incentives for OMPs
- Regulation and incentives for AMR
- Adaptive pathways
- Real-world evidence
- Life-cycle value of innovation

Although there is a large overlap, OHE researchers interested in this research theme want to target funded research contracts that satisfy the members’ intellectual curiosity, i.e. those subjects that are not so much sought-after by the market. To do so, the strategy must be to increase funded research
contracts from private for-profit funders; to attract/win funding from public, non-profit, charities and work on partnerships with Universities, research institutes, and thinktanks/consultancies that are interested in those topics. To apply to research grants by non-profit funders; and promote and chase commercial research contracts for-profit.

A new staff member specialised in Industrial Organisation with a PhD degree and several post-doc positions in the field of the economics of innovation and pharmaceutical R&D to join the OHE in June 2020. The incorporation of a new OHE team member with such theme-relevant background should greatly aid the achievement of the 2020 objectives.

The main challenge for this theme in the short and medium term are the environmental constraints such as Brexit and the pending IRO status, which pose an extra test on the expansion and progression of funding opportunities.

In any case, the main goals of this theme are to expand and diversify the sources of income; to get more funded research projects; to work on collaborations to reach out to more potential funders; and, to target more peer reviewed journal publications of research outputs.

**Selection of hot topics in 2020:**

The lead joint with the OHE team worked in the identification and selection of the most relevant and intellectually interesting topics within the theme of the economics of innovation. The selection process was based on balancing what the market demand with what team members are interested on - the overlap of the two sets identified and listed above. Feedback on the five selected is very welcome. The list that emerged is:

<table>
<thead>
<tr>
<th>Hot Topics in 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Economics of innovation</strong></td>
</tr>
<tr>
<td>1 Outcomes-Based ‘Contracting’: How can Outcome-Based Contracting accelerate market access and manage payers’ uncertainty?</td>
</tr>
<tr>
<td>2 Innovative pricing: How can innovative pricing incentivise Pharmaceutical R&amp;D?</td>
</tr>
<tr>
<td>3 Innovation in the Pharmaceutical Sector: What is the societal benefit of pharmaceutical innovation and how to measure it appropriately?</td>
</tr>
<tr>
<td>4 Pharmaceutical R&amp;D: Is there a role for patent pools and public-private partnerships?</td>
</tr>
<tr>
<td>5 Price Transparency: Who benefits from and what are the negative effects of price transparency? Can confidential prices remain whilst delivering benefits of price transparency?</td>
</tr>
</tbody>
</table>

Incentivising Quality (Margherita Neri)

- At the 2019 OHE Research Away Day the team agreed that the theme name requires a revision. The name ‘Incentivising Quality’ focuses too narrowly on research around incentives and reimbursement schemes, and this does not appropriately reflect what this theme aims to capture in terms of OHE interest and current expertise. This action is in progress and we are expecting to be able to introduce a new, more comprehensive name in Q1 of 2020. Following multiple rounds of discussion and feedback, the most popular name candidate is currently ‘Policy, organisation and incentives in health systems. A renovated and more suitable theme title is expected to bring greater opportunities for internal cohesion and easier identification of our expertise from external funders.

- Other organisations undertaking consultancy/ research work on health systems appear to have been engaged in projects for the UK Department of Health and Social Care and NHS England. OHE could also try to explore opportunities with these clients.
The core research pipeline for this theme looks ‘healthy’. It includes a fair number of projects aiming to develop the necessary expertise to apply to externally funded work, as well as to publish in peer-reviewed journals.

Several research proposals were submitted to prestigious funders in 2019 (e.g. the Health Foundation, NIHR, MRC) but were rejected. The topic areas of these applications concerned inequality of access to cancer screening, adolescent mental health in developing countries and relationship between birth mode/setting and long-term outcomes. OHE needs to identify the reasons for these failures and design effective strategies to resubmit these proposals in 2020.

Main objectives for 2020:

- To obtain another large multi-year research grant. This should help accumulating a stable source of income over the forthcoming years and fill the gap that should be left by the NIHR funded PSS-CQUIN project.
- To develop new or capitalise on existing relationships with other health economics research centres to build opportunities for collaborations and joint grant application submissions. Existing networks include the Private Health Information Network and the Division of Health Service Delivery within the School of Population Health at NYU Langone.
- To strategically promote the use of the core research activities, with the aim to develop research ideas and internal knowledge that can be used to obtain external funding.
- The list that emerged from the theme brainstorming for the 5 hot research topics in this area are:

<table>
<thead>
<tr>
<th>HOT TOPICS IN 2020</th>
<th>Incentivising Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Workforce retention: How can the NHS effectively recruit and retain mental health nurses?</td>
<td></td>
</tr>
<tr>
<td>2. Inequality: How to reduce income-related inequality in access to cancer screening and in health outcomes?</td>
<td></td>
</tr>
<tr>
<td>3. Brexit: What are the effects of Brexit for health care professional retention?</td>
<td></td>
</tr>
<tr>
<td>4. Allocative Efficiency: What is the right weight we should give to prevention, primary care, hospital care and long-term care to maximize health-related outcomes?</td>
<td></td>
</tr>
<tr>
<td>5. Financial and non-financial incentives for providers: How could bettering work conditions of nurses improve retention in the NHS? What are the pull mechanisms for nurses by private health care providers?</td>
<td></td>
</tr>
</tbody>
</table>

Measuring and valuing outcomes (Patricia Cubí-Mollá)

- In 2019, a total of 15 on-going projects are labeled under the Measuring and Valuing Outcomes group, 13 of which are funded research and two correspond to consulting. With a few exceptions, the projects have low budgets and six of them are linked to the EuroQol Foundation. Core research projects on the theme are very scarce, and all of them focus on completing papers rather than as a source of pump-priming for more challenging projects.
- One of the main challenges is to incentivise the collaboration between new OHE staff to create new research pathways and establish the extant ones. The theme-related meeting, and follow-up conversations have provided a wider scope of the potential research topics, and synergies in the group. There is a discussion on new research projects, such as process utilities or incorporation of patient preferences to HTA, and other topics which were already developed (as experience-based values) are now being resurrected and a project should be submitted for core research.
- Currently Mike Herdman is the only member of the OHE staff who is a member of the EuroQol group. A challenge is to create a stronger link between OHE and the EuroQol group, with the...
potential application for membership of those who are undertaking research closer to the group (Chris Sampson, David Mott, Bernarda Zamora, Patricia Cubi-Molla).

OPPORTUNITIES:

- The new OHE masterclass Outcomes-based contracting can be used as a platform to increase the profile of the theme group (e.g., outcome-related projects that can be delivered by OHE) among the relevant stakeholders.
- Recent recruitment has brought experts (Chris Skedgel, Eleanor Bell, Nadine Henderson) with different levels of experience who can help broaden the scope of topics covered by the theme.
- The brainstorming exercise during the Research Away Day about hot topics identified lines of research that can be approached from more than one group. For instance, value-based pricing, or the incorporation of PROMs into HTA decision-making. This presents OHE with an opportunity to build up a strong-based line of research, which could put OHE as a key reference for the topic.

GOALS FOR 2020:

- To keep on promoting group engagement and building capacity. Facilitate conversations and share knowledge of each of the theme-related experts in OHE.
- To suggest at least one speaker for an OHE lunchtime seminar.
- To propose and organise courses and/or issue panels on outcomes-related topics at conferences such as ISPOR, seeking collaboration with external contacts.

The list that emerged from the theme brainstorming for the 5 hot research topics in this area are:

HOT TOPICS IN 2020:

<table>
<thead>
<tr>
<th></th>
<th>Measuring and valuing outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PROs and patient-centred care: What are the opportunities and challenges?</td>
</tr>
<tr>
<td>2</td>
<td>Outcomes based pricing based on PROs: Is it feasible? Is it desirable?</td>
</tr>
<tr>
<td>3</td>
<td>Incorporating patients’ preferences into HTA: Should it be done? If so, how?</td>
</tr>
<tr>
<td>4</td>
<td>Challenges of using PROs: What are the challenges of using PROs in challenging populations (e.g. young, rare diseases)?</td>
</tr>
<tr>
<td>5</td>
<td>Patient experience: How does patient experience affect the measurement and valuation of health outcomes? What is the potential impact?</td>
</tr>
</tbody>
</table>
6 Update on status of Independent Research Organisation Application

The status of Independent Research Organisation is needed by OHE to be allowed to apply to funding calls of UK research councils (Medical Research Council - MRC, and Economic and Social Research Council - ESRC) and other bodies.

We submitted the application to the UK Research and Innovation Office at the end of August 2019. We were assured that the application has ‘gone through’ the ESRC and posteriorly referred to the Department for Business, Energy and Industrial Strategy to review.

At the end of 2019 we were waiting for a response that materialised in February 2020 with the much sought award of the IRO status OHE.
7 Concluding Remarks

They year 2019 was a critical point in the history of OHE. The Executive and Senior management teams had changed almost entirely— with Adrian Towse passing over the directorship, the political environment changing radically, and new challenges faced by the health care system and by the pharmaceutical sector.

OHE’s survival as a well-regarded research centre relied (and still does) on OHE maintaining its strong reputation for producing high quality research in health economics, independent from external pressures or influences. Revenues from our research consultancy help support OHE’s research programme and the attainment of its charitable objects.

To survive in this new environment OHE aims to increase its funding base. Thus, OHE current strategy includes drawing from a more diverse than usual array of funding sources. The goal is to raise more research grants and win more research consultancy projects but, also, to invest in new initiatives that are scalable but do not necessarily involve proportional expansions of manpower (such as our proposed Masterclasses series, etc).

Investing time and effort in seeking funds for strategically critical research topics while producing research of high quality and navigating the evolving socio-economic environment is paramount for OHE to thrive. This is the reason the input of the Research Committee is now more critical than ever.
About us
Founded in 1962 by the Association of the British Pharmaceutical Society, the Office of Health Economics (OHE) is not only the world’s oldest health economics research group, but also one of the most prestigious and influential.

OHE provides market-leading insights and in-depth analyses into health economics & health policy. Our pioneering work informs health care and pharmaceutical decision-making across the globe, enabling clients to think differently and to find alternative solutions to the industry’s most complex problems.

Our mission is to guide and inform the healthcare industry through today’s era of unprecedented change and evolution. We are dedicated to helping policy makers and the pharmaceutical industry make better decisions that ultimately benefit patients, the industry and society as a whole.

OHE. For better health care decisions.

Areas of expertise

- Evaluation of health care policy
- The economics of health care systems
- Health technology assessment (HTA) methodology and approaches
- HTA’s impact on decision making, health care spending and the delivery of care
- Pricing and reimbursement for biologics and pharmaceuticals, including value-based pricing, risk sharing and biosimilars market competition
- The costs of treating, or failing to treat, specific diseases and conditions
- Drivers of, and incentives for, the uptake of pharmaceuticals and prescription medicines
- Competition and incentives for improving the quality and efficiency of health care
- Incentives, disincentives, regulation and the costs of R&D for pharmaceuticals and innovation in medicine
- Capturing preferences using patient-reported outcomes measures (PROMs) and time trade-off (TTO) methodology
- Roles of the private and charity sectors in health care and research
- Health and health care statistics